This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Chloroprocaine parenteral

Updated 2 Feb 2023 | Chloroprocaine


Injectable formulations of chloroprocaine hydrochloride.

Drugs List

  • AMPRES 50mg/5ml injection
  • chloroprocaine 50mg/5ml injection
  • Therapeutic Indications


    Anaesthesia - spinal

    Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes.


    Due to the complexity and specialist nature of using anaesthesia, specific dosing information on this agent is not included.

    When using this agent, specialist literature, national guidelines and Trust policies should be consulted to ensure appropriate dosage and assessment of all relevant patient factors.

    Additional Dosage Information

    Choose the lowest possible dose.

    Administer injection slowly, after having aspirated a minimum quantity of CSF to confirm the correct position.


    For intrathecal use.

    Slowly inject the entire dose and check the patient's vital functions extremely carefully maintaining continuous verbal contact.


    Children under 18 years
    Hypovolaemic shock
    Recent anticoagulant therapy
    Cardiac conduction defects
    Cardiogenic shock
    Severe anaemia

    Precautions and Warnings

    Administration site infection
    Inflammation of injection site
    Plasma cholinesterase deficiency
    Acute porphyria
    Diabetic nephropathy
    Multiple sclerosis
    Neuromuscular disorder
    Severe hepatic disorder
    Severe renal impairment

    Refer to product information for use in peridural/spinal anaesthesia
    Advise ability to drive/operate machinery may be affected by side effects
    Treatment to be initiated and supervised by a specialist
    Administer injection slowly
    Aspirate prior to injection to avoid intravascular administration
    Avoid local anaesthetics if inflammation in region of proposed injection
    Discard any unused portion
    Discontinue immediately if toxic symptoms occur, especially in epidural use
    Do not inject near site of skin infection
    Do not use if any signs of precipitate or particulate matter apparent
    For single use only
    Resuscitation facilities must be immediately available
    Monitor vital signs, respiration & cardiac function
    Use only when equipment adequate for cardiac/respiratory monitoring/support
    Reduce dose in elderly
    Start treatment at lowest recommended dose
    Female: Ensure adequate contraception during treatment

    Pregnancy and Lactation


    Chloroprocaine is contraindicated in pregnancy.

    Animal studies are insufficient with respect to effects on pregnancy and foetal development.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use with caution during breastfeeding.

    It is not known whether chloroprocaine/metabolites are excreted in human milk.

    Based on the low excretion of other local anaesthetics into breast milk and the extremely short half-life of chloroprocaine, it is unlikely to adversely affect the breastfed infant. However an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Anaphylactic reaction
    Anaphylactoid reaction
    Angioneurotic oedema
    Blurred vision
    Cardiac arrest
    Cardiovascular depression
    Cauda equina syndrome
    CNS toxicity
    Faecal incontinence
    Hearing disturbances
    Laryngeal oedema
    Loss of sphincter control
    Motor disturbances
    Muscle weakness
    Myocardial depression
    Neurological damage
    Respiratory arrest
    Respiratory depression
    Rise in body temperature
    Severe hypotension
    Sexual dysfunction
    Speech disturbances
    Tongue numbness
    Urinary incontinence
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2018

    Reference Sources

    Summary of Product Characteristics: Ampres 10mg/ml solution for injection. Sintetica Limited. Revised March 2017.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Chloroprocaine Last revised: 3 November 2017.
    Last accessed: 6 June 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.